Lakefront Biotherapeutics NV (LKFT)
NASDAQ: LKFT · Real-Time Price · USD
29.80
-0.47 (-1.55%)
At close: Jul 13, 2026, 4:00 PM EDT
29.80
0.00 (-0.02%)
After-hours: Jul 13, 2026, 4:04 PM EDT
LKFT Revenue
Lakefront Biotherapeutics NV had revenue of 7.56M EUR in the quarter ending March 31, 2026, a decrease of -90.73%. This brings the company's revenue in the last twelve months to 1.09B, up 234.71% year-over-year. In the year 2025, Lakefront Biotherapeutics NV had annual revenue of 1.17B with 268.41% growth.
Revenue (ttm)
1.09B EUR
Revenue Growth
+234.71%
P/S Ratio
1.64
Revenue / Employee
1,956,505 EUR
Employees
558
Market Cap
1.98B USD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.17B | 849.32M | 268.41% |
| Dec 31, 2024 | 316.42M | 29.43M | 10.25% |
| Dec 31, 2023 | 287.00M | 9.62M | 3.47% |
| Dec 31, 2022 | 277.38M | -3.08M | -1.10% |
| Dec 31, 2021 | 280.46M | -249.81M | -47.11% |
| Dec 31, 2020 | 530.26M | -355.54M | -40.14% |
| Dec 31, 2019 | 885.80M | 578.13M | 187.91% |
| Dec 31, 2018 | 307.67M | 151.75M | 97.33% |
| Dec 31, 2017 | 155.92M | 4.31M | 2.84% |
| Dec 31, 2016 | 151.61M | 91.03M | 150.27% |
| Dec 31, 2015 | 60.58M | -29.44M | -32.70% |
| Dec 31, 2014 | 90.02M | -6.55M | -6.78% |
| Dec 31, 2013 | 96.57M | 4.35M | 4.71% |
| Dec 31, 2012 | 92.23M | -23.06M | -20.01% |
| Dec 31, 2011 | 115.29M | -21.27M | -15.57% |
| Dec 31, 2010 | 136.56M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sarepta Therapeutics | 2.18B |
| Aurinia Pharmaceuticals | 298.30M |
| AnaptysBio | 232.39M |
| Nuvation Bio | 143.05M |
| Intellia Therapeutics | 66.09M |
| Mesoblast | 65.38M |
| Monte Rosa Therapeutics | 42.95M |
| Stoke Therapeutics | 32.08M |
LKFT News
- 4 hours ago - Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi - GlobeNewsWire
- 3 days ago - Lakefront Biotherapeutics resumed with an Equal Weight at Morgan Stanley - TheFly
- 6 days ago - Acquisition of Own Shares - GlobeNewsWire
- 13 days ago - Acquisition of Own Shares - GlobeNewsWire
- 14 days ago - Lakefront Receives Transparency Notification from Madison Avenue Partners - GlobeNewsWire
- 4 weeks ago - Lakefront Biotherapeutics announces EUR 50M share repurchase program - TheFly
- 4 weeks ago - Lakefront Announces Initiation of €50 Million Stock Repurchase Program - GlobeNewsWire
- 5 weeks ago - Lakefront Biotherapeutics appoints Eric Hedrick chief medical officer - TheFly